Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control

Metabolic Profiling in Human Fibroblasts Enables Subtype Clustering in Glycogen Storage Disease

Molecular Diagnosis of Panel-Based Next-Generation Sequencing Approach and Clinical Symptoms in Patients with Glycogen Storage Disease: A Single Center Retrospective Study

Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flowchart

Three novel mutations of the G6PC gene identified in Chinese patients with glycogen storage disease type Ia

Disease-associated programming of cell memory in glycogen storage disorder type 1a

Blood glucose trends in glycogen storage disease type Ia: A cross‐sectional study

Continuous glucose monitoring metrics in people with liver glycogen storage disease and idiopathic ketotic hypoglycemia: A single-center, retrospective, observational study

Personalized management of hepatic glycogen storage disorders: The role of continuous glucose monitoring

Predominance of the c.648G > T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia

Genotypic and phenotypic characteristics of 12 chinese children with glycogen storage diseases

A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs

Molecular mechanisms of catalytic inhibition for active site mutations in glucose-6-phosphatase catalytic subunit 1 linked to glycogen storage disease

Molecular Genetics of Type 1 Glycogen Storage Disease

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing

Diagnosis and Follow‐up of Glycogen Storage Disease (GSD) Type VI from the Largest GSD Center in China

Neurological Characteristics of Pediatric Glycogen Storage Disease

Molecular, Biochemical, and Clinical Characterization of Thirteen Patients with Glycogen Storage Disease 1a in Malaysia

A specific serum lipid signature characterizes patients with glycogen storage disease type Ia

Glycogen storage disease type VI: clinical course and molecular background